Please note that this product was withdrawn from the Community register of designated orphan medicinal products in February 2013 on request of the sponsor.
On 26 November 2010, orphan designation (EU/3/10/809) was granted by the European Commission to Abraxis BioScience Limited, United Kingdom, for nanoparticle albumin-bound paclitaxel for the treatment of pancreatic cancer.
The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in August 2011.
Nanoparticle albumin-bound paclitaxel
Treatment of pancreatic cancer
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Please note that this product was withdrawn from the Community register of designated orphan medicinal products in February 2013 on request of the sponsor, before a marketing authorisation had been granted.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: